3Oldenburg J, Quenzel EM, Harbreeht U, et al. Missense mutations atALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive causeof bleeding during oral anticoagulant therapy. Br J Haematol ,1997,98:240-244.
4Mannucci PM. Genetic control of anticoagulation. Lancet, 1999,353: 688-689.
5Jack H, Valentin F, Jack A,et al. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation, 2003, 107:1692-1711.
6Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med ,1995, 333:11-17.
7Crowther MA, Julian J, McCarty D, et al. Treatment of warfarinassociated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet, 2000,356 : 1551- 1553.
2Bonow RO,Carabello B, de Leon AC Jr, et al.For the ACC/AHA Task Force on Practice Guidelines.Guidelines for the management of patients with valvular heart disease: executive summary.A report of the American College of Cardiology/American Hearst Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease).Circulation,1998,98∶1949-1984.
3Gohlke-Barwolf C, Acar J, Oakley C, et al.Guidelines for prevention of thromboembolic events in valvular heart disease.Eur Heart J,1995,16∶1320-1330.
4Hirsh J, Fuster V.Guide to anticoagulant therapy.Part 2: oral anticoagulants.Circulation,1994,89∶1469-1480.
5Esmunds LH Jr, Clark RE, Cohn LH, et al.Guidelines for reporting morbidity and mortality after cardiac operations. Ann Thorac Surg, 1996, 62∶932-935.
6Huth C, Friedl A, Rost A.Intensity of oral anticoagulation after implantation of St.Jude Medical aortic prosthesis: analysis of the GELIA Database (GELIA 4).Eur Heart J,2001,(Suppl Q)∶Q33-Q38.
7Pruefer D, Dahm M, Dohmen G, et al.Intensity of oral anticoagulation after implantation of St.Jude Medical mital or multiple valve replacement: lessons learned from GELIA (GELIA 5).Eur Heart J,2001,(Suppl Q)∶Q39-Q43.
9Baudet EM, Oca CC, Rouges XF, et al.A 5.5 year experience with the St.Jude Medical cardiac valve prosthesis.Early and late results of 737 valve replacements in 671 patients.J Thorac Cardiovasc Surg,1985,90∶137-144.
10Fernandez J, Laub GW, Akins MS, et al.Early and late phase events after valve replacement with the St.Jude Medical prosthesis in 1200 patients.J Thorac Cardiovasc Surg,1994,107∶394-407.
5Wells PS,Holbrook AM,Crowther NR,et al.Interactions of warfarin with drugs and food[J].Ann Intern Med,1994,121:676-683.
6CURE Study Investigators.Effects of clopidogrel in addition to aspirin in patients with Non-ST elevation:Acute coronary syndromes[J].N Eng Med August,2001,345:494-502.
9Emunds L H. Thmmboembolic complications of current cardiac valvular protheses[J]. Am Surg, 1982, 34(1):96-102.
10White W H, McKittrick T, Takakuwa J, et al. Management and prognosis of life-threatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics[J]. Arch Intem Med, 1996, 156 (2): 1197-1202.
